Premium
The Utility of Cannabidiol in the Treatment of Refractory Epilepsy
Author(s) -
Reddy DS
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.441
Subject(s) - cannabidiol , epilepsy , refractory (planetary science) , medicine , cannabis , pharmacology , psychiatry , biology , astrobiology
Cannabis‐derived cannabinoids such as cannabidiol (CBD) have anticonvulsant properties. Recently, there has been an emerging interest in the use of CBD‐enriched products for treatment of drug‐resistant epilepsy. Some pilot trials of CBD have proved beneficial for refractory epilepsy, but its efficacy is yet to be confirmed by standard placebo‐controlled trials. However, the mechanisms underlying the seizure protection efficacy claims of CBD remain unclear. This review briefly describes the clinical utility of CBD in the treatment of refractory epilepsy.